Aclaris Therapeutics (ACRS) IPO Prices at $11, Well Below Expected Range

Aclaris Therapeutics (NASDAQ: ACRS) priced its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share, below the expected $14-$16 range. The shares are expected to begin trading today on NASDAQ under the ticker symbol "ACRS".

Jefferies LLC and Citigroup Global Markets Inc. are acting as joint book-running managers for the offering. William Blair & Company, L.L.C. is acting as a co-manager.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. Aclaris Therapeutics, Inc. is based in Malvern, Pennsylvania.

You May Also Be Interested In

• Canaccord Starts Aclaris Therapeutis (ACRS) at Buy
• StoneX Reiterates Buy Rating on Zoom Video (ZM)
• Barrick Said To Weigh Delaying North America Gold IPO To 2027 - Bloomberg